4.9 (108) In stock
This video discusses the clinical equivalence of BI 695501 (Cyltezo®; adalimumab-adbm) and adalimumab for rheumatoid arthritis - the VOLTAIRE-RA and extension studies.
How Do Payers See The Adalimumab Biosimilar Story Playing Out In 2023
Evidence for Rheumatoid Arthritis
Sam Cavana on LinkedIn: Symposium on Primary Breast Cancer in Older Women
Sam Cavana on LinkedIn: Safety evaluation of empagliflozin for patients with type 2 diabetes and…
Evidence for Rheumatoid Arthritis
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
Cyltezo® (adalimumab-adbm) Shows Equivalence to Humira®
Adalimumab biosimilar BI 695501 (Cyltezo®; adalimumab-adbm) in rheumatoid arthritis
Evidence for Crohn's Disease
Maurizio Mazzi on LinkedIn: VOLTAIRE-RA and VOLTAIRE-RA extension: Clinical equivalence studies of BI…
Rheumatology Dosing & Administration
